Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948214 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
A Phase 3 study of Growth Hormone Deficiency (GHD), sponsored by Lumos Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 17
- Study locations
NCT06948214 is a Phase 3 study of Growth Hormone Deficiency (GHD) that is actively recruiting participants, run by Lumos Pharma. The registered enrollment target is 150 participants. The trial reports 17 study locations across 15 states.
The verdict
NCT06948214, a Phase 3 study of Growth Hormone Deficiency (GHD), is actively recruiting participants, sponsored by Lumos Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 17
- Study locations
Study Summary
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
Conditions Studied
Interventions
- DRUG LUM-201
- OTHER Matched Placebo (Capsules)
Study Locations (17)
Colorado
- Lumos Pharma Investigational Site - Centennial
- Lumos Pharma Investigational Site - Greenwood Village
Florida
- Lumos Pharma Investigational Site - Orlando
- Lumos Pharma Investigational Site - Tallahassee
Alabama
- Lumos Pharma Investigational Site - Birmingham
California
- Lumos Pharma Investigational Site - Sacramento
District of Columbia
- Lumos Pharma Investigational Site - Washington D.C.
Louisiana
- Lumos Pharma Investigational Site - New Orleans
Minnesota
- Lumos Pharma Investigational Site - Minneapolis
Missouri
- Lumos Pharma Investigational Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948214
The ClinicalTrials.gov registry entry for NCT06948214 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumos Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Growth Hormone Deficiency (GHD) appearing as the primary indexed condition, and to 2 interventions - of which LUM-201 is the first listed.
NCT06948214 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Colorado, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06948214 about?
NCT06948214 is a clinical study titled "Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency". The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to re...
What is the current status of trial NCT06948214?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-04. Estimated completion is 2028-01.
What conditions does trial NCT06948214 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency (GHD).
What interventions are being tested in trial NCT06948214?
The interventions under investigation include: LUM-201 (DRUG), Matched Placebo (Capsules) (OTHER).
Who is sponsoring clinical trial NCT06948214?
This trial is sponsored by Lumos Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948214 being conducted?
This trial has 17 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency (GHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.